Case Details
- Citation: [2022] SGHC 78
- Title: Combe International Ltd v Dr August Wolff GmbH & Co KG Arzneimittel
- Court: High Court of the Republic of Singapore
- Tribunal Appeal No: Tribunal Appeal No 22 of 2021
- Date of Judgment: 7 April 2022
- Judge: Lee Seiu Kin J
- Hearing Date: 4 February 2022
- Plaintiff/Applicant: Combe International Ltd
- Defendant/Respondent: Dr August Wolff GmbH & Co KG Arzneimittel
- Legal Area: Intellectual Property — Trademarks
- Core Statute: Trade Marks Act (Cap 332, 2005 Rev Ed) (“TMA”)
- Key Provisions Referenced: ss 8(2)(b), 8(7)(a), and (not appealed) ss 8(4)(b)(i) and 8(4)(b)(ii)
- Judgment Length: 35 pages, 9,488 words
- Prior Related Decisions: Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] 4 SLR 626; Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] SGIPOS 10
Summary
This case concerns a trademark opposition and appeal arising from the registration of the mark “Dr. Wolff’s VAGISAN”. The plaintiff, Combe International Ltd, owns earlier “VAGISIL” marks used for feminine care products. The defendant, Dr August Wolff GmbH & Co KG Arzneimittel, previously obtained registration of “VAGISAN” but had that registration invalidated by the plaintiff. After the invalidation, the defendant revised the mark by adding “Dr. Wolff’s” and sought registration again in Singapore for goods in Classes 3 and 5.
The High Court dismissed the plaintiff’s appeal from the decision of the Intellectual Property Adjudicator (“IPA”) which had allowed the defendant’s application. The court held that, applying the statutory test under s 8(2)(b) of the Trade Marks Act, the Application Mark was not similar to the plaintiff’s “VAGISIL” marks when assessed visually, aurally, and conceptually, and therefore there was no likelihood of confusion. The court also found that the plaintiff failed to establish the passing-off misrepresentation element under s 8(7)(a).
In addition to resolving the substantive opposition, the judgment is also useful for practitioners because it reiterates the approach to appellate review in trademark registry appeals: there is no requirement to show a “material error of principle” before the High Court intervenes, given that such appeals are by way of rehearing and opposition proceedings turn on legal correctness rather than discretion.
What Were the Facts of This Case?
The plaintiff, Combe International Ltd, was founded in 1949 and markets a range of in-house brands, including “VAGISIL” products for feminine care. The plaintiff held multiple registered “VAGISIL” marks: T9804752H, T9804751Z, T0813410H, and T1112897J. Three of these registrations claimed goods in either Class 3 or Class 5, which is relevant because the defendant’s application also covered goods in those classes.
The defendant is part of the Dr Wolff Group, a family business founded in 1905. The defendant’s business involves research, manufacture, and marketing of dermatological, medicinal, and cosmetic products distributed internationally. The defendant conceived the “VAGISAN” mark in 1994 as a portmanteau of “vagina” and the Latin word “sanitas” (health). It sells intimate care products for women under “VAGISAN” in multiple countries, including Austria, Malaysia, and the United Kingdom.
Before the present appeal, the parties had already litigated in Singapore. The defendant’s original “VAGISAN” registration was invalidated at the instance of the plaintiff. The defendant then attempted to avoid further litigation by revising the mark: it added “Dr. Wolff’s”, which is both the founder’s surname and an existing trademark in Singapore. The defendant filed an application on 25 May 2018 to register the revised mark (the “Application Mark”) in Classes 3 and 5. IPOS accepted and published the application for opposition purposes on 7 December 2018.
The plaintiff opposed the application on 8 April 2019, relying on multiple grounds under the Trade Marks Act, including s 8(2)(b) (relative grounds based on similarity and likelihood of confusion) and s 8(7)(a) (passing off). The IPA rejected the opposition on all four grounds originally relied upon. The plaintiff appealed to the High Court, but did not pursue the grounds under ss 8(4)(b)(i) and 8(4)(b)(ii). Accordingly, the High Court’s analysis focused on s 8(2)(b) and s 8(7)(a).
What Were the Key Legal Issues?
The principal legal issue was whether the Application Mark “Dr. Wolff’s VAGISAN” was similar to the plaintiff’s “VAGISIL” marks for the purposes of s 8(2)(b) of the TMA, and if so, whether the similarity (together with similarity of goods) would give rise to a likelihood of confusion among the relevant public. The court adopted a step-by-step approach: first assessing similarity of the marks and similarity of goods/services, and then considering likelihood of confusion.
Although the parties did not dispute that the goods and services were similar, the plaintiff challenged the IPA’s findings on the marks. Specifically, the plaintiff argued that the IPA erred in treating “Dr. Wolff’s” as distinctive and at least equally distinctive as “VAGISAN”; in concluding that the dominant element was not “VAGISAN”; and in finding that the marks were visually, aurally, and conceptually dissimilar. The plaintiff’s overarching submission was that the Application Mark and the “VAGISIL” marks were dissimilar only in name, but substantively similar in a way that should trigger confusion.
The second issue concerned s 8(7)(a). This provision imports the elements of passing off, requiring the plaintiff to establish misrepresentation leading to damage. The plaintiff contended that the IPA erred in finding that the element of misrepresentation was not established. Thus, the court had to determine whether the Application Mark was likely to mislead consumers into believing there was a commercial connection or endorsement by the plaintiff.
How Did the Court Analyse the Issues?
Before turning to the substantive trademark analysis, the High Court addressed the standard for appellate intervention. The appeal was from an IPA decision. Under O 87 r 4(2) of the Rules of Court, an appeal from the Registrar/registry decision is by way of rehearing. The court therefore rejected any notion that the plaintiff had to demonstrate a “material error of fact or law” or a “material error of principle” before the court could intervene. The court relied on the Court of Appeal’s clarification in Ceramiche Caesar SpA v Caesarstone Sdot-Yam Ltd, which explained that rehearing directs the appellate court to hear the matter afresh.
The court also emphasised why no threshold is required. Trademark opposition proceedings do not involve discretion; they involve legal correctness and entitlement. Further, there is typically no trial with oral evidence at opposition hearings, so the appellate court is in as good a position as the IPA to evaluate the facts. The court noted that the introduction of the new Rules of Court 2021 did not appear to alter these principles for appeals from the IP registry.
On s 8(2)(b), the court applied the step-by-step approach endorsed in The Polo/Lauren Co, LP v Shop In Department Store Pte Ltd. Because there was no dispute as to similarity of goods, the court focused on whether the Application Mark was similar to the “VAGISIL” marks. The court adopted the established framework that substantive similarity is assessed through three aspects: visual, aural, and conceptual similarity. It also reiterated that the analysis is not a mechanical checklist; rather, the court must consider the marks as a whole in context.
Crucially, the court treated distinctiveness as an integral factor within the similarity assessment. Distinctiveness affects how consumers perceive the marks and therefore influences whether the marks are likely to be taken as indicating the same origin. The court relied on Staywell Hospitality Group Pty Ltd v Starwood Hotels & Resorts Worldwide, Inc for the proposition that distinctiveness is not a separate step but is integrated into the visual, aural, and conceptual analysis.
Although the extract provided is truncated, the judgment’s structure indicates that the court conducted a detailed comparison across the three similarity dimensions. It addressed visual similarity first, then aural similarity, and then conceptual similarity. The plaintiff’s arguments were directed at the IPA’s treatment of the elements “Dr. Wolff’s” and “VAGISAN”, including whether “Dr. Wolff’s” was distinctive and whether “VAGISAN” was the dominant element. The court’s analysis therefore necessarily involved determining how the relevant public would likely perceive the mark components, including whether “Dr. Wolff’s” would function as a brand identifier that differentiates the defendant’s goods from the plaintiff’s “VAGISIL” line.
After assessing similarity, the court proceeded to the likelihood of confusion inquiry. Under s 8(2)(b), likelihood of confusion depends on the combined effect of similarity of goods and similarity of marks. The court’s conclusion that the marks were not sufficiently similar meant that the plaintiff could not establish the statutory requirement for confusion. The court therefore upheld the IPA’s decision to allow registration.
On s 8(7)(a), the court considered the passing-off misrepresentation element. The IPA had found that misrepresentation was not established. The plaintiff’s appeal challenged that finding. The High Court’s approach would have required it to consider whether the Application Mark was likely to cause consumers to believe that the defendant’s goods were connected with, endorsed by, or otherwise commercially associated with the plaintiff’s “VAGISIL” products. Given the court’s findings on dissimilarity of the marks, the misrepresentation analysis would also be influenced by whether consumers would actually be misled by the branding and overall presentation of the Application Mark.
What Was the Outcome?
The High Court dismissed the plaintiff’s appeal. The decision of the IPA allowing the defendant’s registration of the Application Mark was therefore upheld. Practically, this meant that the defendant retained the right to register “Dr. Wolff’s VAGISAN” for the relevant goods in Classes 3 and 5, notwithstanding the plaintiff’s earlier “VAGISIL” registrations.
The dismissal also confirmed that the plaintiff’s reliance on s 8(2)(b) and s 8(7)(a) did not succeed on the evidence and legal tests applied. Since the plaintiff did not appeal the IPA’s findings under ss 8(4)(b)(i) and 8(4)(b)(ii), those grounds remained decided against the plaintiff.
Why Does This Case Matter?
This decision is significant for trademark practitioners because it illustrates how Singapore courts approach the similarity analysis under s 8(2)(b), especially where the later mark includes an additional branding element (here, “Dr. Wolff’s”) that may alter the overall impression. The case reinforces that courts will not treat similarity as a purely linguistic exercise; instead, they will evaluate visual, aural, and conceptual impressions as they would be perceived by the relevant public, with distinctiveness integrated into that assessment.
For brand owners, the case also demonstrates the strategic importance of how marks are constructed and presented. The defendant’s attempt to overcome an earlier invalidation by adding “Dr. Wolff’s” was central to the dispute. The court’s acceptance that the marks were not sufficiently similar suggests that adding a distinctive brand identifier can, depending on the circumstances, meaningfully reduce the risk of confusion even where the remaining portion of the mark shares a thematic or phonetic resemblance.
For litigators, the judgment is also useful on procedural and appellate review points. By reiterating that appeals from IP registry decisions are by way of rehearing without a threshold requirement for “material error of principle”, the case provides comfort that the High Court will conduct a full re-evaluation of the legal correctness of the opposition decision. This matters for case strategy: parties should expect the court to engage substantively with the similarity and confusion analysis rather than limiting review to narrow errors.
Legislation Referenced
- Trade Marks Act (Cap 332, 2005 Rev Ed), s 8(2)(b)
- Trade Marks Act (Cap 332, 2005 Rev Ed), s 8(7)(a)
- Trade Marks Act (Cap 332, 2005 Rev Ed), ss 8(4)(b)(i) and 8(4)(b)(ii) (relied upon below but not appealed)
Cases Cited
- Ceramiche Caesar SpA v Caesarstone Sdot-Yam Ltd [2017] 2 SLR 308
- Future Enterprises Pte Ltd v McDonald’s Corp [2007] 2 SLR(R) 845
- Ho Soo Fong v Standard Chartered Bank [2007] 2 SLR(R) 181
- Courts (Singapore) Pte Ltd v Big Box Corp Pte Ltd [2018] 5 SLR 312
- The Polo/Lauren Co, LP v Shop In Department Store Pte Ltd [2006] 2 SLR(R) 690
- Staywell Hospitality Group Pty Ltd v Starwood Hotels & Resorts Worldwide, Inc [2014] 1 SLR 911
- Richemont International SA v Goldlion Enterprise (Singapore) Pte Ltd [2006] 1 SLR(R) 401
- Hai Tong Co (Pte) Ltd v Ventree Singapore Pte Ltd [2013] 2 SLR 941
- Digi International v Teraoka Seiko Co, Ltd [2021] SGHC 165
- Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] 4 SLR 626
- Dr August Wolff GmbH & Co KG Arzneimittel v Combe International Ltd [2021] SGIPOS 10
- [2016] SGIPOS 8
- [2017] SGIPOS 7
- [2018] SGIPOS 1
- [2021] SGIPOS 10
- [2021] SGIPOS 13
- [2021] SGHC 165
- [2022] SGHC 78
Source Documents
This article analyses [2022] SGHC 78 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.